AlphaQuest LLC Buys 38,441 Shares of Kura Oncology, Inc. $KURA

Key Points

• AlphaQuest LLC significantly increased its stake in Kura Oncology, Inc. by 189.1% during the first quarter, owning 58,772 shares valued at approximately $388,000.
• Kura Oncology reported a loss of $0.75 EPS for the most recent quarter, missing analyst expectations by $0.90, with revenue significantly below projections at $15.29 million.
• Analysts have varied target prices for Kura Oncology, with Barclays lowering theirs from $32.00 to $11.00, while the consensus price target stands at $24.10 with a rating of "Moderate Buy."

AlphaQuest LLC grew its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 189.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 58,772 shares of the company's stock after purchasing an additional 38,441 shares during the quarter. AlphaQuest LLC owned about 0.07% of Kura Oncology worth $388,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KURA. Pallas Capital Advisors LLC acquired a new stake in shares of Kura Oncology during the first quarter worth $66,000. Flower City Capital bought a new stake in Kura Oncology during the first quarter valued at $79,000. E Fund Management Co. Ltd. boosted its position in Kura Oncology by 18.9% during the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock valued at $81,000 after acquiring an additional 1,951 shares during the last quarter. Corton Capital Inc. acquired a new stake in Kura Oncology during the 4th quarter worth about $99,000. Finally, Exchange Traded Concepts LLC raised its position in shares of Kura Oncology by 117.8% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,474 shares of the company's stock worth $115,000 after acquiring an additional 9,450 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on KURA. JMP Securities cut their target price on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research report on Monday, August 11th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. Mizuho reduced their price objective on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, May 19th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Finally, Wall Street Zen raised shares of Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Kura Oncology presently has an average rating of "Moderate Buy" and an average price target of $24.10.

Kura Oncology Stock Performance

KURA stock traded up $0.05 during mid-day trading on Tuesday, hitting $7.95. The company had a trading volume of 1,863,833 shares, compared to its average volume of 1,898,629. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $21.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The stock's fifty day moving average price is $6.51 and its two-hundred day moving average price is $6.57. The firm has a market cap of $690.06 million, a PE ratio of -3.52 and a beta of 0.19.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The business had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. On average, analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.